Developer docs
API playgroundTry for free, no card

Search company profiles

Emitech

Full company profile

uuid003a74t

Namestring
Emitech
Legal namestring
Emitech, Inc.
Websiteurl
emitechinc.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Emitech, Inc. is a biotechnology company founded in 2002 and headquartered in Fall River, Massachusetts that develops nanotechnology-based biosensors and optoelectronic devices for chemical and biological detection. Its platform centers on proprietary nanoporous silicon (NPSi) photonic crystals, electrochemical sensor arrays, and bio-nanocomposites engineered to deliver particle-per-trillion-level sensitivity for narcotics, explosives, and disease biomarkers. The product portfolio includes the OpiTest family (electrochemical wearable and bench-top detectors), OpiDrop (rapid fentanyl sweat/saliva/urine test), OpiSweat (wrist-worn wearable), Fenta-strips and Fenta-Test Cassettes (colorimetric lateral flow assays with 0.5 ng/mL LoD), and pipeline products CLEBO (women's health diagnostics) and a COVID-19 electrochemical immunosensor; underlying detection claims include 1 ng/mL fentanyl detection in sweat and explosives detection down to 150 femtograms.

The company's business model rests on SBIR/STTR federal grant funding — most notably a $2.5 million three-year NIH/NIDA Phase II grant (2022) for the wearable opioid sensor program, plus cumulative awards across MDA, USAF, US Army, US Navy, NSF and DHS — together with development contracts from private healthcare and life-sciences clients. Distribution today is essentially direct: R&D contracts to federal agencies and private-sector validation partners, with planned future sales of devices and disposable cartridges via direct channels and a recently signed manufacturing partnership with Linxens for scaling. Customer segments are vertically structured around federal defense and health agencies, private healthcare/life-sciences companies, and eventually consumer health end-users.

Emitech currently operates with 1-10 employees, is privately held and founder-controlled (Co-founder/CEO Marina Katayeva and CSO Dr. Igor A. Levitsky), and is in a pre-commercial execution phase building manufacturing partnerships, regulatory pathways, and channel readiness to monetize the electrochemical sensor platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersFall River, United States
HQ citystring
Fall River
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanotechnology biosensors, opioid detection devices, electrochemical immunosensors, fentanyl test strips, wearable diagnostics
Industry3 codes
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code4 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Analytical Laboratory Instrument Manufacturing334516
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code3 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biosensors & Diagnostic Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Government SBIR/STTR Contracts
TypeOthers
Description

Emitech generates revenue primarily through Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants from federal agencies including NIH/NIDA, NSF, MDA, US Army, US Navy, Department of Homeland Security, and Department of State. The company has received 8 Phase I and 3 Phase II SBIR/STTR contracts.

emitechinc.com
2Private Sector Contracts
TypeProfessional Services
Description

Revenue from private sector clients in the life sciences and material science markets, including development agreements and product validation contracts.

emitechinc.com
3Product Sales (Future)
TypeHardware Sales
Description

Once products reach market, revenue will be generated from sale of electrochemical devices (OpiTest, OpiDrop, OpiSweat), fentanyl test strips (Fenta-strips, Fenta-Test Cassette), and disposable cartridges for wearable devices.

emitechinc.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1OpiTest
Description

Electrochemical devices for rapid and accurate narcotic detection in sweat (wearable), saliva, urine, and dissolved medication. Narcotic panel includes fentanyl with a limit of detection (LoD) of 1ng/ml.

emitechinc.com
+5 more records
Core offering1 text field

Emitech develops and is commercializing nanotechnology-based electrochemical biosensors and lateral flow immunoassay devices for ultra-sensitive detection of narcotics (opioids/fentanyl), explosives, and disease biomarkers. Current and pipeline products include wearable and bench-top electrochemical detectors (OpiTest, OpiDrop, OpiSweat) and rapid colorimetric fentanyl test strips/cassettes, with women's-health (CLEBO) and COVID-19 electrochemical immunosensors under development. The company primarily delivers these technologies via government SBIR/STTR R&D contracts and is preparing direct sales and OEM manufacturing channels for commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Limit of detection of 1 ng/ml for opioids in human sweat (vs. 10-20 ng/ml market standard)
+5 more records
Product overview1 text field

Emitech offers a portfolio of electrochemical and lateral flow immunoassay products for narcotics detection and medical diagnostics. Core products include OpiTest (electrochemical multi-matrix detection platform), OpiDrop (fentanyl-specific e-sensor), OpiSweat (wearable wrist device), Fenta-strips, and Fenta-Test Cassettes (colorimetric rapid tests). These products share foundational electrochemical sensor technology and Bluetooth connectivity for wireless data transfer. Future pipeline includes CLEBO (women's health diagnostics) and COVID-19 rapid testing platform. All products are under development with SBIR funding from NIH/NIDA.

Product and service7 records
1OpiTest
CategoryBiosensor devices for narcotics detection
Description

Electrochemical detection platform for rapid and accurate narcotic detection in sweat (wearable), saliva, urine, and dissolved medication, with a fentanyl limit of detection of 1 ng/ml. Targeted at government agencies, healthcare providers, and law-enforcement/laboratory users requiring multi-matrix rapid opioid screening.

2OpiDrop
CategoryBiosensor devices for narcotics detection
Description

Urine/saliva/pill electrochemical sensor (e-sensor) for rapid fentanyl detection with LoD of 1 ng/ml, 10-minute time-to-result, and wireless data transmission to phone/tablet/PC. Targeted at point-of-care testers, harm-reduction programs, and clinical/research users needing fast fentanyl-specific screening.

3OpiSweat
CategoryWearable biosensor devices
Description

Wrist-worn wearable device for non-invasive, rapid narcotics detection in human sweat with quantitative results in 10 minutes and wireless connectivity to smartphone/tablet/PC. Features a reusable device with disposable cartridges for cost-effective continuous monitoring, targeted at medical monitoring, addiction treatment, and at-risk-workforce applications.

4Fenta-strips
CategoryRapid diagnostic test strips
Description

Colorimetric lateral flow immunoassay strip sensors for rapid fentanyl detection with LoD of 0.5 ng/ml, providing semi-quantitative concentration readings well below the 20 ng/ml typical of market-available strips. Targeted at harm-reduction organizations, clinicians, and field-deployment users needing low-cost rapid fentanyl screening.

5Fenta-Test Cassette
CategoryRapid diagnostic test cassettes
Description

Colorimetric cassette-format lateral flow immunoassay for rapid fentanyl detection, providing semi-quantitative results indicating fentanyl concentration ranges through color-change readouts. Targeted at users needing an easy-to-read cassette format for fentanyl field-testing.

6CLEBO
CategoryWomen's-health diagnostics (under development)
Description

Under-development portable non-invasive rapid diagnostic device using menstrual fluid and blood to target gynecological cancers, breast cancer, sexually transmitted infections, Alzheimer's disease, and physiological parameters (pH, glucose, cholesterol, ketones, salts) with Bluetooth connectivity. Targeted at consumers and clinicians seeking home-based women's-health and disease-monitoring diagnostics.

7COVID-19 Rapid Test
CategoryViral diagnostics (under development)
Description

Under-development non-invasive rapid electrochemical immunosensor for COVID-19 providing 5–10 minute results at $3–5 per test cartridge, with a limit of detection of 1,000–10,000 virion/ml (comparable to PCR) and wireless communication to smartphone/PC. Targeted at point-of-care users, employers, and healthcare providers needing PCR-grade rapid screening.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-11-01
Description

Emitech teams up with Linxens, a global leader in electronics production with Healthcare solutions in Biosensor, Stick to skin and Track&Trace, for a successful manufacturing partnership. Linxens leads healthcare business development specializing in biosensors and wearable solutions with 15+ years experience in healthcare, digital security, and telecommunications.

2Inertia, Inc.
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-07-01
Description

Emitech forged a connection with Inertia, Inc. leveraging their expertise in low-volume production and commercialization of innovative biomedical devices.

emitechinc.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

Emitech was chosen among top startups for the competitive M2D2 accelerator program. This strategic move connects Emitech to vital expertise and resources, propelling technology development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-01
Description

Strategic alliance with CytoDiagnostics, Inc., a partner and manufacturer of components for OpiTest, an electrochemical detection device. CytoDiagnostics developed unique approaches to ensure highest quality antibody conjugates with ultra-low LOD for fentanyl detection.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-10-01
Description

Emitech joined MassBio, a community of leaders dedicated to growing the life sciences industry and adding value to the healthcare system. MassBio provides networking, advocacy, and resources for biotechnology companies in Massachusetts.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-09-01
Description

Emitech became a member of Mansfield Bio-Incubator, Biotech Entrepreneurship in the Boston area. The incubator provides mentorship, resources, and networking opportunities for biotech startups, culminating in pitch competition participation and nondilutive funding awards.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Emitech

Biosensors & Diagnostic Devicesemitechinc.com

What Emitech does

Emitech, Inc. is a biotechnology company founded in 2002 and headquartered in Fall River, Massachusetts that develops nanotechnology-based biosensors and optoelectronic devices for chemical and biological detection. Its platform centers on proprietary nanoporous silicon (NPSi) photonic crystals, electrochemical sensor arrays, and bio-nanocomposites engineered to deliver particle-per-trillion-level sensitivity for narcotics, explosives, and disease biomarkers. The product portfolio includes the OpiTest family (electrochemical wearable and bench-top detectors), OpiDrop (rapid fentanyl sweat/saliva/urine test), OpiSweat (wrist-worn wearable), Fenta-strips and Fenta-Test Cassettes (colorimetric lateral flow assays with 0.5 ng/mL LoD), and pipeline products CLEBO (women's health diagnostics) and a COVID-19 electrochemical immunosensor; underlying detection claims include 1 ng/mL fentanyl detection in sweat and explosives detection down to 150 femtograms.

The company's business model rests on SBIR/STTR federal grant funding — most notably a $2.5 million three-year NIH/NIDA Phase II grant (2022) for the wearable opioid sensor program, plus cumulative awards across MDA, USAF, US Army, US Navy, NSF and DHS — together with development contracts from private healthcare and life-sciences clients. Distribution today is essentially direct: R&D contracts to federal agencies and private-sector validation partners, with planned future sales of devices and disposable cartridges via direct channels and a recently signed manufacturing partnership with Linxens for scaling. Customer segments are vertically structured around federal defense and health agencies, private healthcare/life-sciences companies, and eventually consumer health end-users.

Emitech currently operates with 1-10 employees, is privately held and founder-controlled (Co-founder/CEO Marina Katayeva and CSO Dr. Igor A. Levitsky), and is in a pre-commercial execution phase building manufacturing partnerships, regulatory pathways, and channel readiness to monetize the electrochemical sensor platform.

Emitech firmographics

Firmographics
Name
Emitech
Legal name
Emitech, Inc.
Website
https://emitechinc.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Emitech industry classification

Industry
Product category
Biosensors & Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Nanotechnology biosensors
  • Opioid detection devices
  • Electrochemical immunosensors
  • Fentanyl test strips
  • Wearable diagnostics

Where Emitech is headquartered

Location

Headquarters

HQ city
Fall River
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Emitech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Government SBIR/STTR Contracts: Emitech generates revenue primarily through Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants from federal agencies including NIH/NIDA, NSF, MDA, US Army, US Navy, Department of Homeland Security, and Department of State. The company has received 8 Phase I and 3 Phase II SBIR/STTR contracts.
  2. Private Sector Contracts: Revenue from private sector clients in the life sciences and material science markets, including development agreements and product validation contracts.
  3. Product Sales (Future): Once products reach market, revenue will be generated from sale of electrochemical devices (OpiTest, OpiDrop, OpiSweat), fentanyl test strips (Fenta-strips, Fenta-Test Cassette), and disposable cartridges for wearable devices.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Emitech product offering

Product offering

Core offering

Emitech develops and is commercializing nanotechnology-based electrochemical biosensors and lateral flow immunoassay devices for ultra-sensitive detection of narcotics (opioids/fentanyl), explosives, and disease biomarkers. Current and pipeline products include wearable and bench-top electrochemical detectors (OpiTest, OpiDrop, OpiSweat) and rapid colorimetric fentanyl test strips/cassettes, with women's-health (CLEBO) and COVID-19 electrochemical immunosensors under development. The company primarily delivers these technologies via government SBIR/STTR R&D contracts and is preparing direct sales and OEM manufacturing channels for commercialization.

Product overview

Emitech offers a portfolio of electrochemical and lateral flow immunoassay products for narcotics detection and medical diagnostics. Core products include OpiTest (electrochemical multi-matrix detection platform), OpiDrop (fentanyl-specific e-sensor), OpiSweat (wearable wrist device), Fenta-strips, and Fenta-Test Cassettes (colorimetric rapid tests). These products share foundational electrochemical sensor technology and Bluetooth connectivity for wireless data transfer. Future pipeline includes CLEBO (women's health diagnostics) and COVID-19 rapid testing platform. All products are under development with SBIR funding from NIH/NIDA.

Differentiator

Problem solved

Functional benefit

Brands

  • OpiTest: Electrochemical devices for rapid and accurate narcotic detection in sweat (wearable), saliva, urine, and dissolved medication. Narcotic panel includes fentanyl with a limit of detection (LoD) of 1ng/ml.
  • OpiDrop
  • OpiSweat
  • Fenta-strips
  • Fenta-Test Cassette
  • CLEBO

Products and services

  • OpiTest Electrochemical detection platform for rapid and accurate narcotic detection in sweat (wearable), saliva, urine, and dissolved medication, with a fentanyl limit of detection of 1 ng/ml. Targeted at government agencies, healthcare providers, and law-enforcement/laboratory users requiring multi-matrix rapid opioid screening.
  • OpiDrop Urine/saliva/pill electrochemical sensor (e-sensor) for rapid fentanyl detection with LoD of 1 ng/ml, 10-minute time-to-result, and wireless data transmission to phone/tablet/PC. Targeted at point-of-care testers, harm-reduction programs, and clinical/research users needing fast fentanyl-specific screening.
  • OpiSweat Wrist-worn wearable device for non-invasive, rapid narcotics detection in human sweat with quantitative results in 10 minutes and wireless connectivity to smartphone/tablet/PC. Features a reusable device with disposable cartridges for cost-effective continuous monitoring, targeted at medical monitoring, addiction treatment, and at-risk-workforce applications.
  • Fenta-strips Colorimetric lateral flow immunoassay strip sensors for rapid fentanyl detection with LoD of 0.5 ng/ml, providing semi-quantitative concentration readings well below the 20 ng/ml typical of market-available strips. Targeted at harm-reduction organizations, clinicians, and field-deployment users needing low-cost rapid fentanyl screening.
  • Fenta-Test Cassette Colorimetric cassette-format lateral flow immunoassay for rapid fentanyl detection, providing semi-quantitative results indicating fentanyl concentration ranges through color-change readouts. Targeted at users needing an easy-to-read cassette format for fentanyl field-testing.
  • CLEBO Under-development portable non-invasive rapid diagnostic device using menstrual fluid and blood to target gynecological cancers, breast cancer, sexually transmitted infections, Alzheimer's disease, and physiological parameters (pH, glucose, cholesterol, ketones, salts) with Bluetooth connectivity. Targeted at consumers and clinicians seeking home-based women's-health and disease-monitoring diagnostics.
  • COVID-19 Rapid Test Under-development non-invasive rapid electrochemical immunosensor for COVID-19 providing 5–10 minute results at $3–5 per test cartridge, with a limit of detection of 1,000–10,000 virion/ml (comparable to PCR) and wireless communication to smartphone/PC. Targeted at point-of-care users, employers, and healthcare providers needing PCR-grade rapid screening.

Quantifiable outcome

  • Limit of detection of 1 ng/ml for opioids in human sweat (vs. 10-20 ng/ml market standard)
  • +5 more outcomes

Companies that use Emitech

Customer profile

Segments3 records

Ideal customer profiles2 records

Emitech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Emitech partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • LinxenscoreOEM/ Whitelabel/ Licensing Partner · 1 November 2024Emitech teams up with Linxens, a global leader in electronics production with Healthcare solutions in Biosensor, Stick to skin and Track&Trace, for a successful manufacturing partnership. Linxens leads healthcare business development specializing in biosensors and wearable solutions with 15+ years experience in healthcare, digital security, and telecommunications.
  • Inertia, Inc.coreImplementation/ SI/ Consulting Partner · 1 July 2024Emitech forged a connection with Inertia, Inc. leveraging their expertise in low-volume production and commercialization of innovative biomedical devices.
  • M2D2 (Massachusetts Medical Device Development Center)minorStrategic or Co-development Partner · 1 December 2023Emitech was chosen among top startups for the competitive M2D2 accelerator program. This strategic move connects Emitech to vital expertise and resources, propelling technology development.
  • CytoDiagnostics, Inc.coreStrategic or Co-development Partner · 1 April 2023Strategic alliance with CytoDiagnostics, Inc., a partner and manufacturer of components for OpiTest, an electrochemical detection device. CytoDiagnostics developed unique approaches to ensure highest quality antibody conjugates with ultra-low LOD for fentanyl detection.
  • MassBio (Massachusetts Biotechnology Council)minorStrategic or Co-development Partner · 1 October 2022Emitech joined MassBio, a community of leaders dedicated to growing the life sciences industry and adding value to the healthcare system. MassBio provides networking, advocacy, and resources for biotechnology companies in Massachusetts.
  • Mansfield Bio-IncubatorminorStrategic or Co-development Partner · 1 September 2022Emitech became a member of Mansfield Bio-Incubator, Biotech Entrepreneurship in the Boston area. The incubator provides mentorship, resources, and networking opportunities for biotech startups, culminating in pitch competition participation and nondilutive funding awards.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emitech competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Emitech social profiles

Digital presence

Emitech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Emitech leadership team

Management profile

Number of profiles

Profiles7 records

Emitech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Emitech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emitech

What does Emitech do?

Emitech develops and is commercializing nanotechnology-based electrochemical biosensors and lateral flow immunoassay devices for ultra-sensitive detection of narcotics (opioids/fentanyl), explosives, and disease biomarkers. Current and pipeline products include wearable and bench-top electrochemical detectors (OpiTest, OpiDrop, OpiSweat) and rapid colorimetric fentanyl test strips/cassettes, with women's-health (CLEBO) and COVID-19 electrochemical immunosensors under development. The company primarily delivers these technologies via government SBIR/STTR R&D contracts and is preparing direct sales and OEM manufacturing channels for commercialization.

Is Emitech a public or private company?

Emitech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Emitech founded?

Emitech was founded in 2002. It employs 1 to 10 people.

Where is Emitech based?

Emitech is headquartered in Fall River, United States, in the North America region.

How does Emitech make money?

Three revenue lines are on record. Government SBIR/STTR Contracts are the primary driver. The others are private Sector Contracts and product Sales (Future).

Does Emitech have an API?

No public API is recorded for Emitech.

What industry is Emitech in?

Emitech's product category is Biosensors & Diagnostic Devices. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales